Literature DB >> 15274411

Instruments for quality of life assessment in patients with gastrointestinal cancer.

A G Pallis1, I A Mouzas.   

Abstract

Health-related quality of life (HRQoL) is a multi-dimensional concept, encompassing all aspects of patient health and used widely as an outcome measure in clinical trials. In this review, the current status of HRQoL assessment in clinical studies of gastrointestinal cancer is examined and the various instruments proposed for this purpose are considered and compared. The cancer-specific questionnaires, among them the Spitzer Quality of Life Index, the Rotterdam Symptom Check List, the Functional Living Index-Cancer, the Functional Assessment of Cancer Therapy General (FACT-G) and the Quality of Life Questionnaire of the European Organization for Research and Treatment in Cancer (EORTC), provide essential information about particular concerns of cancer patients and are most sensitive in detecting changes over time. The domain-specific questionnaires, among them the Multidimensional Fatigue Inventory, the McGill Pain Questionnaire, the Hospital Anxiety and Depression Scale and the Anorectal Sphincter-Conservative Treatment Questionnaire, are designed to assess one specific domain of quality of life. The core-module cancer-specific questionnaires combine a core questionnaire for use in any type of cancer with a module questionnaire which assesses specific issues in cancer patient subgroups. Such core-module instruments have been evaluated for colorectal, pancreatic, hepatobiliary, oesophageal and gastric cancer. The most valid and standardized instruments for HRQoL assessment in cancer patients are the EORTC and the FACT questionnaires, which are widely used in Europe and around the world. Data provided by these specific instruments complement clinical outcomes and may help to evaluate the costs and benefits of different treatment options, thus being essential to further improvement of treatment and care of cancer patients.

Entities:  

Mesh:

Year:  2004        PMID: 15274411

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Doctor, what are my options? A prospective cohort study of an individualized care plan for patients with gastrointestinal cancer.

Authors:  A E Hird; M Lemke; M Turovsky; V Malecki; K Kumar; C DeAngelis; E Chow; Y J Ko
Journal:  Curr Oncol       Date:  2015-06       Impact factor: 3.677

2.  A Finnish Version of RAND-36-Item Health Survey Versus Structured Interview 8 Years Postoperatively.

Authors:  Iina Saimanen; Viivi Kuosmanen; Jukka Harju; Tuomas Selander; Samuli Aspinen; Matti Eskelinen
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

3.  Effects of Home Care on patients with hepatocellular carcinoma treated with sorafenib.

Authors:  Monika Moser; Iuliana-Pompilia Radu; Jean-François Dufour
Journal:  JGH Open       Date:  2021-07-06

4.  The Effect of ACE Inhibitor on the Quality of Life amongst Patients with Cancer Cachexia.

Authors:  Mehdi Dehghani; Mehdi Mirzaie; Pouya Farhadi; Alireza Rezvani
Journal:  Asian Pac J Cancer Prev       Date:  2020-02-01

5.  Validity and Reliability of the Amharic Version of EORTC-QLQ-CR29 Among Colorectal Cancer Patients in Ethiopia.

Authors:  Aynalem Abraha Woldemariam; Lidya Genene Abebe; Abigiya Wondimagegnehu; Bizu Gelaye; Eva Johanna Kantelhardt; Adamu Addissie
Journal:  Cancer Manag Res       Date:  2021-12-21       Impact factor: 3.989

6.  Comparison of health-related quality of life with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil chemotherapy regimens as first-line systemic therapy in locally advanced inoperable or metastatic gastric or gastro-esophageal junction adenocarcinoma: A prospective study from South India.

Authors:  K Govind Babu; Tamojit Chaudhuri; K C Lakshmaiah; Lokanatha Dasappa; Linu Abraham Jacob; M C Suresh Babu; A H Rudresha; K N Lokesh; L K Rajeev
Journal:  South Asian J Cancer       Date:  2018 Jan-Mar
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.